{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:15:42Z","timestamp":1765545342924,"version":"3.32.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2005,10,19]],"date-time":"2005-10-19T00:00:00Z","timestamp":1129680000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1038\/sj.npp.1300940","type":"journal-article","created":{"date-parts":[[2005,10,19]],"date-time":"2005-10-19T17:32:43Z","timestamp":1129743163000},"page":"1869-1879","source":"Crossref","is-referenced-by-count":79,"title":["Antipsychotic-Like vs Cataleptogenic Actions in Mice of Novel Antipsychotics Having D2 Antagonist and 5-HT1A Agonist Properties"],"prefix":"10.1038","volume":"31","author":[{"given":"Laurent","family":"Bardin","sequence":"first","affiliation":[]},{"given":"Mark S","family":"Kleven","sequence":"additional","affiliation":[]},{"given":"Catherine","family":"Barret-Gr\u00e9voz","sequence":"additional","affiliation":[]},{"given":"Ronan","family":"Depoort\u00e8re","sequence":"additional","affiliation":[]},{"given":"Adrian","family":"Newman-Tancredi","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2005,10,19]]},"reference":[{"key":"BF1300940_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0014-2999(97)01207-7","volume":"334","author":"MB Assi\u00e9","year":"1997","unstructured":"Assi\u00e9 MB, Cosi C, Koek W (1997). 5-HT1A receptor agonist properties of the antipsychotic nemonapride: comparison with bromerguride and clozapine. Eur J Pharmacol 334: 141\u2013147.","journal-title":"Eur J Pharmacol"},{"key":"BF1300940_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/026988110101500108","volume":"15","author":"RA Bantick","year":"2001","unstructured":"Bantick RA, Deakin JFW, Grasby PM (2001). The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics ? J Psychopharmacol. 15: 37\u201346.","journal-title":"J Psychopharmacol."},{"key":"BF1300940_CR3","first-page":"PG20","volume":"14","author":"RA Bantick","year":"2000","unstructured":"Bantick RA, Montgomery AJ, Malek N, Choudry T, Messa C, Deakin JFW et al (2000). Occupancy\/downregulation of the 5-HT1A receptor by clozapine measured using PET scanning. J Psychopharmacol 14: PG20.","journal-title":"J Psychopharmacol"},{"key":"BF1300940_CR4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00702-003-0094-7","volume":"111","author":"GD Bartoszyk","year":"2004","unstructured":"Bartoszyk GD, Van Amsterdam C, Greiner HE, Rautenberg W, Russ H, Seyfried CA (2004). Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile. J Neural Transm 111: 113\u2013126.","journal-title":"J Neural Transm"},{"key":"BF1300940_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0006-3223(02)01643-8","volume":"53","author":"P Blier","year":"2003","unstructured":"Blier P, Ward NM (2003). Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry 53: 193\u2013203.","journal-title":"Biol Psychiatry"},{"key":"BF1300940_CR6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0893-133X(95)00068-O","volume":"13","author":"N Brunello","year":"1995","unstructured":"Brunello N, Masotto C, Steardo L, Markstein R, Racagni G (1995). New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology 13: 177\u2013213.","journal-title":"Neuropsychopharmacology"},{"key":"BF1300940_CR7","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1176\/appi.ajp.159.6.1035","volume":"159","author":"RW Buchanan","year":"2002","unstructured":"Buchanan RW, Kreyenbuhl J, Zito JM, Lehman A (2002). Relationship of the use of adjunctive pharmacological agents to symptoms and level of function in schizophrenia. Am J Psychiatry 159: 1035\u20131043.","journal-title":"Am J Psychiatry"},{"key":"BF1300940_CR8","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s00213-002-1256-2","volume":"166","author":"YH Chou","year":"2003","unstructured":"Chou YH, Halldin C, Farde L (2003). Occupancy of 5-HT1A receptors by clozapine in the primate brain: a PET study. Psychopharmacology 166: 234\u2013240.","journal-title":"Psychopharmacology"},{"key":"BF1300940_CR9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S0893-133X(97)00176-0","volume":"18","author":"CL Christoffersen","year":"1998","unstructured":"Christoffersen CL, Meltzer LT (1998). Reversal of haloperidol-induced extrapyramidal side effects in cebus monkeys by 8-hydroxy-2-(di-n-propylamino) tetralin and its enantiomers. Neuropsychopharmacology 18: 399\u2013402.","journal-title":"Neuropsychopharmacology"},{"key":"BF1300940_CR10","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1038\/sj.npp.1300262","volume":"28","author":"Y Claustre","year":"2003","unstructured":"Claustre Y, Peretti DD, Brun P, Gueudet C, Allouard N, Alonso R et al (2003). SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. I: Neurochemical and electrophysiological profile. Neuropsychopharmacology 28: 2064\u20132076.","journal-title":"Neuropsychopharmacology"},{"key":"BF1300940_CR11","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s00213-002-1043-0","volume":"162","author":"D Cussac","year":"2002","unstructured":"Cussac D, Duqueyroix D, Newman-Tancredi A, Millan MJ (2002). Stimulation by antipsychotic agents of mitogen-activated protein kinase (MAPK) coupled to cloned, human (h) serotonin 5-HT1A receptors. Psychopharmacology 162: 168\u2013177.","journal-title":"Psychopharmacology"},{"key":"BF1300940_CR12","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0893-133X(98)00090-6","volume":"20","author":"DG Daniel","year":"1999","unstructured":"Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M (1999). Ziprasidone 80\u2009mg\/day and 160\u2009mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 20: 491\u2013505.","journal-title":"Neuropsychopharmacology"},{"key":"BF1300940_CR13","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1038\/sj.npp.1300261","volume":"28","author":"R Depoortere","year":"2003","unstructured":"Depoortere R, Boulay D, Perrault G, Bergis O, Decobert M, Francon D et al (2003). SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity. Neuropsychopharmacology 28: 1889\u20131902.","journal-title":"Neuropsychopharmacology"},{"key":"BF1300940_CR14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0014-2999(95)00234-C","volume":"281","author":"EA Forster","year":"1995","unstructured":"Forster EA, Cliffe IA, Bill DJ, Dover GM, Jones D, Reilly Y et al (1995). A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635. Eur J Pharmacol 281: 81\u201388.","journal-title":"Eur J Pharmacol"},{"key":"BF1300940_CR15","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/BF00433091","volume":"69","author":"PJ Fray","year":"1980","unstructured":"Fray PJ, Sahakian BJ, Robbins TW, Koob GF, Iversen SD (1980). An observational method for quantifying the behavioural effects of dopamine agonists: contrasting effects of d-amphetamine and apomorphine. Psychopharmacology 69: 253\u2013259.","journal-title":"Psychopharmacology"},{"key":"BF1300940_CR16","doi-asserted-by":"publisher","first-page":"S277","DOI":"10.1016\/S0924-977X(02)80381-9","volume":"12","author":"J Glennon","year":"2002","unstructured":"Glennon J, McCreary AC, Ronken E, Siarey R, Hesselink MB, Feenstra R et al (2002). SLV313 is a dopamine D2 receptor antagonist and serotonin 5-HT1A receptor agonist: In vitro and in vivo neuropharmacology. Eur Neuropsychopharmacol 12: S277.","journal-title":"Eur Neuropsychopharmacol"},{"key":"BF1300940_CR17","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1177\/026988110401800308","volume":"18","author":"T Hirose","year":"2004","unstructured":"Hirose T, Uwahodo Y, Yamada S, Miwa T, Kikuchi T, Kitagawa H et al (2004). Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol 18: 375\u2013383.","journal-title":"J Psychopharmacol"},{"key":"BF1300940_CR18","doi-asserted-by":"publisher","first-page":"13432","DOI":"10.1073\/pnas.96.23.13432","volume":"96","author":"GD Honey","year":"1999","unstructured":"Honey GD, Bullmore ET, Soni W, Varatheesan M, Williams SCR, Sharma T (1999). Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc Nat Acad Sci USA 96: 13432\u201313437.","journal-title":"Proc Nat Acad Sci USA"},{"key":"BF1300940_CR19","volume-title":"Bioassay","author":"JJ Hubert","year":"1984","unstructured":"Hubert JJ (1984). Bioassay. Kendall\/Hunt: Dubuque, IA."},{"key":"BF1300940_CR20","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/S0006-8993(99)02346-X","volume":"858","author":"J Ichikawa","year":"2000","unstructured":"Ichikawa J, Meltzer HY (2000). The effect of serotonin1A receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens. Brain Res 858: 252\u2013263.","journal-title":"Brain Res"},{"key":"BF1300940_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/0014-2999(96)00498-0","volume":"313","author":"M Kleven","year":"1996","unstructured":"Kleven M, Prinssen EPM, Koek W (1996). Role of 5-HT1A receptors in the ability of mixed 5-HT1A receptor agonist\/dopamine D2 receptor antagonists to inhibit methylphenidate-induced behaviors in rats. Eur J Pharmacol 313: 25\u201334.","journal-title":"Eur J Pharmacol"},{"key":"BF1300940_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.neuropharm.2005.02.005","volume":"49","author":"MS Kleven","year":"2005","unstructured":"Kleven MS, Barret-Gr\u00e9voz C, Bruins-Slot L, Newman-Tancredi A (2005). Novel antipsychotics agents with 5-HT1A agonist properties: role of 5-HT1A receptor activation in attenuation of catalepsy induction in rats. Neuropharmacology 49: 135\u2013143.","journal-title":"Neuropharmacology"},{"key":"BF1300940_CR23","first-page":"503","volume":"02","author":"MS Kleven","year":"2004","unstructured":"Kleven MS, Barret-Gr\u00e9voz C, Newman-Tancredi A (2004). In vivo pharmacology of novel antipsychotics with diverse dopamine D2 and serotonin 5-HT1A properties: evidence for lowered EPS liability. Coll Inter NeuroPsychopharmacol Abs 02: 503.","journal-title":"Coll Inter NeuroPsychopharmacol Abs"},{"key":"BF1300940_CR24","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0014-2999(01)01011-1","volume":"420","author":"W Koek","year":"2001","unstructured":"Koek W, Vacher B, Cosi C, Assi\u00e9 MB, Patoiseau JF, Pauwels PJ et al (2001). 5-HT1A receptor activation and antidepressant-like effects: F13714 has high efficacy and marked antidepressant potential. Eur J Pharmacol 420: 103\u2013112.","journal-title":"Eur J Pharmacol"},{"key":"BF1300940_CR25","first-page":"2149","volume":"5","author":"Y Kudo","year":"1989","unstructured":"Kudo Y, Ikawa G, Kawakita Y, Saito M, Sakai T, Nakajima T et al (1989). A double-blind comparative study of a new benzamide compound YM-09151 with sulpiride in schizophrenia. J Clin Ther Med 5: 2149\u20132175.","journal-title":"J Clin Ther Med"},{"key":"BF1300940_CR26","first-page":"6","volume":"163","author":"EV Kuzhikandathil","year":"2004","unstructured":"Kuzhikandathil EV, Sayed N, Pasuit JB, Bartoszyk GD (2004). Differential effects of sarizotan on dopamine receptor function. Soc Neurosci Abs 163: 6.","journal-title":"Soc Neurosci Abs"},{"key":"BF1300940_CR27","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/S0893-133X(98)00099-2","volume":"20","author":"CP Lawler","year":"1999","unstructured":"Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA et al (1999). Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20: 612\u2013627.","journal-title":"Neuropsychopharmacology"},{"key":"BF1300940_CR28","first-page":"99","volume":"96","author":"JT Litchfield","year":"1949","unstructured":"Litchfield JT, Wilcoxon F (1949). A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96: 99\u2013113.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF1300940_CR29","doi-asserted-by":"publisher","first-page":"S274","DOI":"10.1016\/S0924-977X(02)80374-1","volume":"12","author":"AC McCreary","year":"2002","unstructured":"McCreary AC, Glennon J, Tuinstra T, Herremans AHJ, Van der Heyden JAM, Feenstra R et al (2002). SLV313: A novel antipsychotic with additional antidepressant and anxiolytic-like actions. Eur Neuropsychopharmacology 12: S274.","journal-title":"Eur Neuropsychopharmacology"},{"key":"BF1300940_CR30","first-page":"1277","volume-title":"Psychopharmacology: The Fourth Generation of Progress","author":"HY Meltzer","year":"1995","unstructured":"Meltzer HY (1995). Atypical antipsychotic drugs. In: Bloom FE, Kupfer DJ (eds). Psychopharmacology: The Fourth Generation of Progress. Raven Press Ltd: New York. pp 1277\u20131288."},{"key":"BF1300940_CR31","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.pnpbp.2003.09.010","volume":"27","author":"HY Meltzer","year":"2003","unstructured":"Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003). Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuro-psychopharmacol Biol Psychiatr 27: 1159\u20131172.","journal-title":"Prog Neuro-psychopharmacol Biol Psychiatr"},{"key":"BF1300940_CR32","first-page":"853","volume":"295","author":"MJ Millan","year":"2000","unstructured":"Millan MJ (2000). Improving the treatment of schizophrenia: Focus on serotonin 5- HT1A receptors. J Pharmacol Exp Ther 295: 853\u2013861.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF1300940_CR33","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/S0022-3565(24)37732-8","volume":"286","author":"MJ Millan","year":"1998","unstructured":"Millan MJ, Schreiber R, Dekeyne A, Rivet JM, Bervoets K, Mavridis M et al (1998). S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol. J Pharmacol Exp Ther 286: 1356\u20131373.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF1300940_CR34","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/00004714-198704000-00010","volume":"7","author":"NC Moore","year":"1987","unstructured":"Moore NC, Meyendorff E, Yeragani V, LeWitt PA, Gershon S (1987). Tiaspirone in schizophrenia. J Clinical Psychopharmacology 7: 98\u2013101.","journal-title":"J Clinical Psychopharmacology"},{"key":"BF1300940_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1461145704005000","volume":"8","author":"A Newman-Tancredi","year":"2005","unstructured":"Newman-Tancredi A, Assi\u00e9 MB, Leduc N, Ormi\u00e8re AM, Danty N, Cosi C (2005). Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacol 8: 1\u201316.","journal-title":"Int J Neuropsychopharmacol"},{"key":"BF1300940_CR36","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0014-2999(98)00483-X","volume":"355","author":"A Newman-Tancredi","year":"1998","unstructured":"Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verri\u00e8le L et al (1998). Agonist and antagonist actions of antipsychotic agents at serotonin 5-HT1A receptors: a [35S]GTP\u03b3S binding study. Eur J Pharmacol 355: 245\u2013256.","journal-title":"Eur J Pharmacol"},{"key":"BF1300940_CR37","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1177\/026988119300700311","volume":"7","author":"C Pantelis","year":"1993","unstructured":"Pantelis C, Barnes TRE (1993). Acute exacerbation of psychosis with buspirone ? J Psychopharmacol 7: 295\u2013300.","journal-title":"J Psychopharmacol"},{"key":"BF1300940_CR38","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0014-2999(02)02430-5","volume":"453","author":"EP Prinssen","year":"2002","unstructured":"Prinssen EP, Colpaert FC, Koek W (2002). 5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur J Pharmacol 453: 217\u2013221.","journal-title":"Eur J Pharmacol"},{"key":"BF1300940_CR39","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s002130050124","volume":"128","author":"EPM Prinssen","year":"1996","unstructured":"Prinssen EPM, Kleven MS, Koek W (1996). Effects of dopamine antagonists in a two-way active avoidance procedure in rats: interactions with 8-OH-DPAT, ritanserin, and prazosin. Psychopharmacology 128: 191\u2013197.","journal-title":"Psychopharmacology"},{"key":"BF1300940_CR40","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0014-2999(98)00536-6","volume":"356","author":"EPM Prinssen","year":"1998","unstructured":"Prinssen EPM, Kleven MS, Koek W (1998). The cataleptogenic effects of the neuroleptic nemonapride are attenuated by its 5-HT1A receptor agonist properties. Eur J Pharmacol 356: 189\u2013192.","journal-title":"Eur J Pharmacol"},{"key":"BF1300940_CR41","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s002130050972","volume":"144","author":"EPM Prinssen","year":"1999","unstructured":"Prinssen EPM, Kleven MS, Koek W (1999). Interactions between neuroleptics and 5-HT1A ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects. Psychopharmacology 144: 20\u201329.","journal-title":"Psychopharmacology"},{"key":"BF1300940_CR42","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0014-2999(00)00178-3","volume":"395","author":"EPM Prinssen","year":"2000","unstructured":"Prinssen EPM, Koek W, Kleven MS (2000). Effects of WAY 100635 on antipsychotic-induced catalepsy in 5-HT depleted animals: a role for tonic activation of 5-HT1A receptors. Eur J Pharmacol 395: 143\u2013147.","journal-title":"Eur J Pharmacol"},{"key":"BF1300940_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF00634146","volume":"50","author":"P Protais","year":"1976","unstructured":"Protais P, Costentin J, Schwartz JC (1976). Climbing behaviour induced by apomorphine in mice: a simple test for the study of dopamine receptors in striatum. Psychopharmacology 50: 1\u20136.","journal-title":"Psychopharmacology"},{"key":"BF1300940_CR44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0014-2999(97)81951-6","volume":"338","author":"H Rollema","year":"1997","unstructured":"Rollema H, Lu Y, Schmidt AW, Zorn SH (1997). Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur J Pharmacol 338: 3\u20135.","journal-title":"Eur J Pharmacol"},{"key":"BF1300940_CR45","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nrd1346","volume":"3","author":"BL Roth","year":"2004","unstructured":"Roth BL, Sheffler DJ, Kroeze WK (2004). Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discovery 3: 353\u2013359.","journal-title":"Nat Rev Drug Discovery"},{"key":"BF1300940_CR46","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/0166-4328(96)00088-5","volume":"73","author":"C Routledge","year":"1996","unstructured":"Routledge C (1996). Development of 5-HT1A receptor antagonists. Behav Brain Res 73: 153\u2013156.","journal-title":"Behav Brain Res"},{"key":"BF1300940_CR47","first-page":"101","volume":"275","author":"TF Seeger","year":"1995","unstructured":"Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA et al (1995). Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 275: 101\u2013113.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF1300940_CR48","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","volume":"28","author":"DA Shapiro","year":"2003","unstructured":"Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR et al (2003). Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28: 1400\u20131411.","journal-title":"Neuropsychopharmacology"},{"key":"BF1300940_CR49","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1176\/appi.ajp.158.10.1722","volume":"158","author":"T Sumiyoshi","year":"2001","unstructured":"Sumiyoshi T, Matsui M, Nohara S, Yamashita I, Kurachi M, Sumiyoshi C et al (2001a). Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am Journal of Psychiatry 158: 1722\u20131725.","journal-title":"Am Journal of Psychiatry"},{"key":"BF1300940_CR50","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/S0006-3223(00)01025-8","volume":"49","author":"T Sumiyoshi","year":"2001","unstructured":"Sumiyoshi T, Matsui M, Yamashita I, Nohara S, Kurachi M, Uehara T et al (2001b). The effect of tandospirone, a serotonin1A agonist, on memory function in schizophrenia. Biol Psychiatry 49: 861\u2013868.","journal-title":"Biol Psychiatry"},{"key":"BF1300940_CR51","volume-title":"Manual of Pharmacological Calculations with Computer Programs","author":"RJ Tallarida","year":"1987","unstructured":"Tallarida RJ, Murray RG (1987). Manual of Pharmacological Calculations with Computer Programs. Springer Verlag: New York."},{"key":"BF1300940_CR52","first-page":"19","volume":"894","author":"T Tuinstra","year":"2002","unstructured":"Tuinstra T, Herremans AHJ, McCreary AC, Van der Heyden JAM, Long SK, Van Hess R et al (2002). SLV314: Behavioral profile of a molecule combining dopamine D2 receptor antagonism with serotonin reuptake inhibition. Soc Neurosci Abs 894: 19.","journal-title":"Soc Neurosci Abs"},{"key":"BF1300940_CR53","first-page":"4","volume":"163","author":"JD Urban","year":"2004","unstructured":"Urban JD, Gay EA, Mailman RB (2004). Functional selectivity as a mechanism of action of newer atypical antipsychotic drugs. Soc Neurosci Abs 163: 4.","journal-title":"Soc Neurosci Abs"},{"key":"BF1300940_CR54","first-page":"1","volume-title":"Working Methods in Neuropsychopharmacology","author":"JL Waddington","year":"1986","unstructured":"Waddington JL (1986). Psychopharmacological studies in rodents: stereotaxic intracerebral injections and behavioral assessment. In: Joseph MH, Waddington JL (eds). Working Methods in Neuropsychopharmacology. Manchester University Press: Manchester. pp 1."},{"key":"BF1300940_CR55","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/0149-7634(95)00057-7","volume":"20","author":"ML Wadenberg","year":"1996","unstructured":"Wadenberg ML (1996). Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat. Neurosci Biobehav Rev 20: 325\u2013339.","journal-title":"Neurosci Biobehav Rev"},{"key":"BF1300940_CR56","first-page":"72","volume":"4","author":"W Wolf","year":"2003","unstructured":"Wolf W (2003). DU127090. Current Opin Invest Drugs 4: 72\u201376.","journal-title":"Current Opin Invest Drugs"},{"key":"BF1300940_CR57","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0924-9338(99)80690-7","volume":"13","author":"K Yoshida","year":"1998","unstructured":"Yoshida K, Sugita T, Higuchi H, Hishikawa Y (1998). Effect of tandospirone on tardive dyskinesia and parkinsonian symptoms. Eur Psychiatry 13: 421\u2013422.","journal-title":"Eur Psychiatry"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/1300940.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/1300940","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/1300940.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T02:16:56Z","timestamp":1736043416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1300940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,19]]},"references-count":57,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["BF1300940"],"URL":"https:\/\/doi.org\/10.1038\/sj.npp.1300940","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"type":"print","value":"0893-133X"},{"type":"electronic","value":"1740-634X"}],"subject":[],"published":{"date-parts":[[2005,10,19]]}}}